Therapeutic Potential of PDA@CeO2 in Suppressing Hepatic Stellate Cell Activation and Preventing Liver Fibrosis

This study demonstrates the potential of PDA@CeO₂ NPs as a novel treatment for liver fibrosis. These nanoparticles scavenge ROS and modulate inflammatory pathways, targeting key signaling mechanisms like the NOX4-TGF-β/Smad3 pathway. PDA@CeO₂ NPs offer a promising strategy for attenuating fibrosis at cellular and molecular levels. Additionally, 2D-SWE provides a non-invasive tool for monitoring therapeutic outcomes, positioning PDA@CeO₂ NPs as a promising candidate for future clinical liver fibrosis treatments.